NicOx Research alliances

Co-development of non-core compounds

Partnership agreements are a key part of NicOx’ business strategy, allowing the Company to focus on its lead products, while maximizing the value of its portfolio of development compounds in non-core therapeutic areas.

NicOx’ partners are chosen based on their expertise and commitment to research and development in areas that are outside of NicOx’ core focus on inflammation and cardiovascular diseases.

These co-development agreements provide NicOx with a broad and differentiated pipeline. Current collaborations are focused on respiratory disorders and liver disease.

Orexo AB
Allergic Rhinitis

In June 2001, NicOx signed a research and co-development agreement on a novel class of nitric oxide-donating respiratory therapeutics with Biolipox, a Swedish company. In November 2007, Orexo AB another Swedish specialty pharmaceutical company acquired Biolipox AB. Through this collaboration NicOx benefits from Orexo’s expertise in identifying and developing compounds for the treatment of airway diseases. The lead product from this collaboration, NCX 1510, is in clinical development for allergic rhinitis and has already completed two phase 1/2a studies, where it has demonstrated a significant reduction in nasal symptoms, combined with a rapid onset of action.

Under the terms of the agreement NicOx will receive a proportional share of all future revenues which result from the collaboration.

TOPIGEN Pharmaceuticals Inc.
Chronic Obstructive Pulmonary Disease (COPD) / Asthma

In October 2005 NicOx signed a license and development agreement with TOPIGEN Pharmaceuticals Inc., a Canadian company, for the development of TPI 1020 (formerly NCX 1020) in Chronic Obstructive Pulmonary Disease (COPD) and other respiratory disorders. Through this collaboration, NicOx benefits from TOPIGEN's strong research and development expertise in the respiratory area. TPI 1020 is a novel respiratory anti-inflammatory, which has completed phase 2 and phase 1 studies with promising results. In November 2007 TOPIGEN initiated a phase 2 trial for TPI 1020 in COPD patients

Under the terms of the agreement, TOPIGEN has rights to TPI 1020 in North America and the option to obtain rest-of-world rights from NicOx at a later date. TOPIGEN will manage and fund all further development activities, through to product registration, under the supervision of a joint management committee. NicOx stands to receive milestone payments, commercial success fees and a share in future revenues from TOPIGEN.